

Peaches Biotech receives 598,000 euros from the CDTI for its PRS project on advanced therapies

- The Center for Technological Development and Innovation (CDTI), of the Ministry of Science and Innovation, has approved a project of the Spanish company Peaches Biotech, considering it highly innovative, providing it with 598,000 euros.
- The selected research represents a disruptive advance in the field of advanced therapies, as it lays the foundations for the development of a platform of biological drugs with regenerative and immunomodulatory effects on different tissues.

Madrid, 13th April 2023.- The Spanish biotechnology group Peaches Biotech, a company specialized in advanced therapies, has been considered as highly innovative by the Center for Technological Development and Innovation (CDTI), which depends on the Spanish Ministry of Science and Innovation, by approving the project "development of a tissue-specific transfer solution for the optimization of cell nesting in advanced therapies" and granting it 598,000 € as a loan with a non-refundable tranche.

In this way, the Spanish Group obtains public financial support, which means an economic injection for the development of its R&D projects, as well as support for its research work to provide patients and professionals with innovative drugs based on advanced therapies.

This is not the first time that the Ministry of Science and Innovation of Spain has recognized the scientific and technological work of the Peaches Group, since last year the State Research Agency (AEI), which depends on the same Ministry, approved two projects in its Public-Private Collaboration Program.

The activity carried out by the Group is considered to be disruptive, since its developments will give rise to a platform of highly innovative biological drugs (PRS), as has also been corroborated by the AEMPS (Spanish Agency of Medicines and Health Products). The potential of this platform is the generation of more than 20 different biological drugs, based on a proprietary cell co-culture patent. The procedure involves the use of stem cell secretomes for cell signaling in different types of tissues, which produces a regenerative and immunomodulatory effect on these tissues and their immune response.

Nota de prensa

In the words of the company's CEO, Juan Carlos de Gregorio: "*CDTI's approval of our PRS project is the scientific certification of our approach and capacity to generate complex biological drugs based on the discovery of the language with which immune cells communicate with different tissues*".

The recognition of the Ministry of Science and Innovation places Peaches Biotech in the group of promising Spanish technology companies working to bring to the patient innovative drugs based on advanced therapies, which will lead to an improvement in the quality of life and health of citizens, as well as an economic impact on the market.